NAPLEX Oncology Review — Soleil Pharmacy Boards Prep™

Master Oncology Pharmacotherapy for the NAPLEX

The NAPLEX Oncology Review covers the high-yield cancer pharmacotherapy principles tested on the NAPLEX. From chemotherapy mechanisms to supportive care management, this guide prepares you to apply oncology drug knowledge with clinical confidence.

Topics Covered

• Chemotherapy Mechanisms: alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, platinum compounds
• Targeted Therapy: tyrosine kinase inhibitors, monoclonal antibodies, CDK4/6 inhibitors, PARP inhibitors
• Immunotherapy: checkpoint inhibitors (PD-1, PD-L1, CTLA-4), CAR-T therapy, immune-related adverse events
• Hormone Therapy: breast cancer (tamoxifen, aromatase inhibitors), prostate cancer (ADT, enzalutamide)
• Hematologic Malignancies: ALL, AML, CLL, CML, multiple myeloma, lymphoma treatment regimens
• Solid Tumor Pharmacotherapy: lung, breast, colorectal, prostate, ovarian cancer — standard of care regimens
• Supportive Care: antiemetics (CINV), G-CSF, erythropoiesis-stimulating agents, bisphosphonates
• Chemotherapy Toxicities: cardiotoxicity, nephrotoxicity, neurotoxicity, myelosuppression management
• Dose Modifications: renal and hepatic impairment adjustments for chemotherapy agents
• High-yield drug tables and treatment algorithm summaries throughout

Soleil Scientific Rating™

⭐⭐⭐⭐⭐ — Oncology pharmacotherapy is complex but high-yield. Master the mechanisms and the toxicities and the NAPLEX questions become manageable.

Advancing Science. Empowering People. — Soleil Scientific Group